The Efficacy of Azvudine and Paxlovid in High-risk Patients With COVID-19: A Prospective Randomized Controlled Trial

This is a randomized controlled clinical study on the clinical efficacy of Azvudine and Paxlovid antivirus therapy in COVID-19 patients with high-risk. The objective is to examine the effect of high-risk on the time for COVID-19 patients to achieve 2 continuously negative SARS-CoV-2 nucleic acid test result, and the RT-PCR negative conversion rates in day 7. Patients who meet inclusion criteria will be randomized into the Azvudine group (treatment group) and Paxlovid group (control group).

Inclusion Criteria:Patients aged 18-85 years (inclusive).Meet the diagnostic criteria for COVID-19.At least one high risk factor for progression to severe COVID-19No more than 5 days from the onset of clinical symptomsSign informed consent form.Exclusion Criteria:Severe or critically patients with COVID-19Have received neutralizing antibodies or convalescent plasma therapy due to COVID-19Child-Pugh grade C or acute liver failureChronic renal failure (eGFR<30 mL/min)Grade III or IV cardiac function, or known left ventricular ejection fraction < 30%Known or suspected history of active or extrapulmonary tuberculosisPatients who are allergic to the active ingredient of the drugPregnant and lactating women